Navidea Biopharmaceuticals Announces Presentation Of Lymphoseek Data At Society Of Surgical Oncology Meeting

DUBLIN, OHIO--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that data from its Lymphoseek® (technetium Tc 99m tilmanocept) injection studies in melanoma, breast and oral cavity squamous cell cancers (SCC) will be presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Houston, TX, March 25-28, 2015.

Help employers find you! Check out all the jobs and post your resume.